Half-year report · Q2

Period2024-01-01 → 2024-06-30
Filed2024-08-02
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 56
MetricValuePeriodScopeSource row
Revenue¥1.11T2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥589.4bn2024-04-01 → 2024-06-30dCons.Revenue IFRS
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥947.5bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥499.2bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Operating income¥126.3bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income¥34.3bn2024-04-01 → 2024-06-30dCons.Operating profit loss IFRS
Operating income¥130.7bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥53.9bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Profit before tax¥142.2bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥42.1bn2024-04-01 → 2024-06-30dCons.Profit loss before tax IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥138.8bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥59.6bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥107.8bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥30.4bn2024-04-01 → 2024-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥102.6bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥41.2bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥110.6bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥31.7bn2024-04-01 → 2024-06-30dCons.Profit loss IFRS
Net income¥105.1bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥42.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Total assets¥3.66Tat 2024-06-30Cons.Assets IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.31Tat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥993.9bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥2.67Tat 2024-06-30Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.47Tat 2023-06-30Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥2.62Tat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.43Tat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥485.9bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥498.7bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥133.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥113.5bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥159.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥54.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥26.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥46.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥198.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥56.032024-04-01 → 2024-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥189.062023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥75.852023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
Equity ratio71.6%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio73.4%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 88
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-06-30¥56.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-06-30¥29.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-06-30¥54.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-06-30¥28.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-06-30¥880m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-06-30¥4.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-06-30¥2.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-06-30−¥890m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-06-30−¥890m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥24.2bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-06-30−¥13.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2024-04-01 → 2024-06-30¥8.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2024-04-01 → 2024-06-30¥8.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥3m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-04-01 → 2024-06-30¥1m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-06-30¥12.3bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2024-04-01 → 2024-06-30¥8.0bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2024-04-01 → 2024-06-30¥145.6bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-04-01 → 2024-06-30¥145.6bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥15m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-04-01 → 2024-06-30¥8m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥37.3bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-04-01 → 2024-06-30¥20.5bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-04-01 → 2024-06-30¥407.1bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-04-01 → 2024-06-30¥407.1bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥96.0bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-04-01 → 2024-06-30¥16.2bn
—segment totalrevenue2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue2024-04-01 → 2024-06-30¥590.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue external2024-04-01 → 2024-06-30¥589.4bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-06-30¥890m
—segment totalsegment profit2024-01-01 → 2024-06-30¥150.5bn
—segment totalsegment profit2024-04-01 → 2024-06-30¥47.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-06-30¥55.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥27.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-06-30¥53.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥26.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-06-30¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥920m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-06-30¥4.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥1.5bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥965m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥965m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥25.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥12.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-06-30¥17.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2023-04-01 → 2023-06-30¥9.2bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-06-30¥17.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2023-04-01 → 2023-06-30¥9.2bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥9m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥4m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-06-30¥8.1bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2023-04-01 → 2023-06-30¥5.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-06-30¥226.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2023-04-01 → 2023-06-30¥122.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-06-30¥226.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-04-01 → 2023-06-30¥122.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥54m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥40m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-06-30¥7.0bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-04-01 → 2023-06-30−¥3.8bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-06-30¥650.4bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-04-01 → 2023-06-30¥340.9bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-06-30¥650.4bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-04-01 → 2023-06-30¥340.9bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-06-30¥136.3bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-04-01 → 2023-06-30¥62.7bn
—segment totalrevenue2023-01-01 → 2023-06-30¥949.2bn
—segment totalrevenue2023-04-01 → 2023-06-30¥500.2bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥947.5bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥499.2bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥1.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥965m
—segment totalsegment profit2023-01-01 → 2023-06-30¥156.1bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥66.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 877
ItemContextValueUnit
Profit loss attributable to non controlling interests IFRSCurrentQuarterDuration1310000000JPY
Profit loss IFRSPrior1QuarterDuration42395000000JPY
Profit loss IFRSCurrentQuarterDuration31728000000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration75.85
Basic earnings loss per share IFRSCurrentQuarterDuration56.03
Diluted earnings loss per share IFRSPrior1QuarterDuration-
Diluted earnings loss per share IFRSCurrentQuarterDuration-
Profit loss IFRSPrior1YTDDuration105058000000JPY
Profit loss IFRSCurrentYTDDuration110625000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration203000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration292000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration10393000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration5389000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration102000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration202000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration10700000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration5884000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration92649000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration121996000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration18000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-65000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration23959000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration26099000000JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration116628000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration148031000000JPY
Other comprehensive income IFRSPrior1YTDDuration127328000000JPY
Other comprehensive income IFRSCurrentYTDDuration153915000000JPY
Comprehensive income IFRSPrior1YTDDuration232387000000JPY
Comprehensive income IFRSCurrentYTDDuration264541000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration228677000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration260182000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration3710000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration4358000000JPY
Comprehensive income IFRSPrior1YTDDuration232387000000JPY
Comprehensive income IFRSCurrentYTDDuration264541000000JPY
Profit loss IFRSPrior1QuarterDuration42395000000JPY
Profit loss IFRSCurrentQuarterDuration31728000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration183000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration143000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration6267000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration373000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration69000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration98000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration6521000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration615000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration82883000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration64659000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration-12000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration-5000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration16427000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass